SelenBio on Netcapital

antibacterial technology for a wide variety of use cases

Raise to date: $110,808

Reporting Date: 04/05/2020

Key Stats

Minimum Raise


Maximum Raise


Likelihood of Max Unlikely
Start Date


Stop Date


Days Remaining


Security Type

Common Stock

Investment Minimum


Deal Type

No Review

Investment Summary



# of Investors

Not Known

% of Minimum Raised


% of Maximum Raised


Dollars Per Day to Reach Max


DPD* Committed


DPD* Category


DPD* All Companies


Kingscrowd Momentum


Total Dollars Raised


Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

SelenBio, a biotechnology company with a post-money valuation of $20.7 million, is raising funds on NetCapital. The company develops an antibacterial technology that prevents the formation of biofilm in dental, medical, industrial, and consumer applications. SelenBio uses a unique selenium-based compound, SELDOX, to keep the applications infection-free. The company was founded by Kenny Gallagher and Karl Doenges. The proceeds of the current crowdfunding round, with a minimum target of $10,000 and a maximum target of $1,070,000, will be used for research & development, operations, completion of current projects, sales & marketing, and compensation for managers. SelenBio is working on multiple projects with excellent traction and has already received the FDA approval for SELDOX.